| NCT03095274 |
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin |
https://ClinicalTrials.gov/show/NCT03095274 |
Recruiting |
Grupo Espanol de Tumores Neuroendocrinos |
2020-06-30 |
| NCT02936323 |
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers |
https://ClinicalTrials.gov/show/NCT02936323 |
Active, not recruiting |
Tarveda Therapeutics |
2020-07-31 |
| NCT02685553 |
Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project |
https://ClinicalTrials.gov/show/NCT02685553 |
Completed |
Universita di Verona |
2016-10-31 |
| NCT03365791 |
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03365791 |
Active, not recruiting |
Novartis |
2019-02-21 |
| NCT04427787 |
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET |
https://ClinicalTrials.gov/show/NCT04427787 |
Recruiting |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2023-11-30 |
| NCT03375320 |
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT03375320 |
Recruiting |
National Cancer Institute (NCI) |
2021-01-01 |
| NCT03335670 |
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03335670 |
Recruiting |
University of Iowa |
2021-10-01 |
| NCT03289741 |
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide |
https://ClinicalTrials.gov/show/NCT03289741 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-09-30 |
| NCT03279601 |
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT03279601 |
Recruiting |
Peking University |
2019-09-01 |
| NCT03278379 |
Avelumab in G2-3 NET |
https://ClinicalTrials.gov/show/NCT03278379 |
Active, not recruiting |
Sunnybrook Health Sciences Centre |
2020-01-11 |
| NCT03278275 |
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 |
https://ClinicalTrials.gov/show/NCT03278275 |
Recruiting |
Rigshospitalet, Denmark |
2020-12-31 |
| NCT03273712 |
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) |
https://ClinicalTrials.gov/show/NCT03273712 |
Recruiting |
University of Iowa |
2020-01-31 |
| NCT03271281 |
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 |
https://ClinicalTrials.gov/show/NCT03271281 |
Recruiting |
Rigshospitalet, Denmark |
2020-09-01 |
| NCT03220217 |
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) |
https://ClinicalTrials.gov/show/NCT03220217 |
Completed |
Ipsen |
2019-07-25 |
| NCT03217097 |
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents |
https://ClinicalTrials.gov/show/NCT03217097 |
Recruiting |
Hospices Civils de Lyon |
2021-07-31 |
| NCT03211988 |
Entinostat Neuroendocrine (NE) Tumor |
https://ClinicalTrials.gov/show/NCT03211988 |
Recruiting |
Columbia University |
2019-08-31 |
| NCT03206060 |
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma |
https://ClinicalTrials.gov/show/NCT03206060 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-01-01 |
| NCT03183271 |
Proton Boost for Locally Advanced HEAD AND NECK TUMORS |
https://ClinicalTrials.gov/show/NCT03183271 |
Completed |
CNAO National Center of Oncological Hadrontherapy |
2015-03-30 |
| NCT03167853 |
Study of JS001 in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03167853 |
Completed |
Peking University |
2018-12-11 |
| NCT03147768 |
Laser Tissue Welding - Distal Pancreatectomy Sealing Study |
https://ClinicalTrials.gov/show/NCT03147768 |
Recruiting |
Laser Tissue Welding, Inc. |
2020-07-01 |
| NCT03145857 |
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use |
https://ClinicalTrials.gov/show/NCT03145857 |
Recruiting |
AHS Cancer Control Alberta |
2031-12-31 |
| NCT03143946 |
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT03143946 |
Completed |
University Medical Center Groningen |
2019-08-31 |
| NCT03136328 |
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan |
https://ClinicalTrials.gov/show/NCT03136328 |
Completed |
Montefiore Medical Center |
2017-03-31 |
| NCT03110978 |
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT03110978 |
Recruiting |
M.D. Anderson Cancer Center |
2022-06-30 |
| NCT03083210 |
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET |
https://ClinicalTrials.gov/show/NCT03083210 |
Recruiting |
Samsung Medical Center |
2020-02-29 |
| NCT03079440 |
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03079440 |
Recruiting |
Asan Medical Center |
2020-12-31 |
| NCT03074513 |
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors |
https://ClinicalTrials.gov/show/NCT03074513 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-31 |
| NCT03070301 |
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03070301 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-02-28 |
| NCT03049189 |
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients |
https://ClinicalTrials.gov/show/NCT03049189 |
Recruiting |
ITM Solucin GmbH |
2023-12-31 |
| NCT03044977 |
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03044977 |
Active, not recruiting |
University of Iowa |
2020-12-31 |
| NCT03042416 |
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety |
https://ClinicalTrials.gov/show/NCT03042416 |
Recruiting |
University of Alberta |
2021-12-31 |
| NCT03037385 |
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03037385 |
Recruiting |
Blueprint Medicines Corporation |
2021-12-31 |
| NCT03034200 |
Phase 2 Study of ONC201 in Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03034200 |
Recruiting |
Case Comprehensive Cancer Center |
2020-09-30 |
| NCT03012789 |
Surgical Intervention and the NETest |
https://ClinicalTrials.gov/show/NCT03012789 |
Active, not recruiting |
Wren Laboratories LLC |
2021-12-31 |
| NCT03001349 |
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03001349 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT02955069 |
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) |
https://ClinicalTrials.gov/show/NCT02955069 |
Completed |
Novartis |
2018-08-10 |
| NCT02943733 |
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs |
https://ClinicalTrials.gov/show/NCT02943733 |
Recruiting |
University of Wisconsin, Madison |
2021-08-31 |
| NCT02939651 |
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02939651 |
Active, not recruiting |
Fox Chase Cancer Center |
2020-09-30 |
| NCT02923934 |
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers |
https://ClinicalTrials.gov/show/NCT02923934 |
Active, not recruiting |
Olivia Newton-John Cancer Research Institute |
2023-08-31 |
| NCT02859064 |
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres |
https://ClinicalTrials.gov/show/NCT02859064 |
Active, not recruiting |
SCRI Development Innovations, LLC |
2020-04-30 |
| NCT02842749 |
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China |
https://ClinicalTrials.gov/show/NCT02842749 |
Active, not recruiting |
Novartis |
2024-12-02 |
| NCT02840149 |
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors |
https://ClinicalTrials.gov/show/NCT02840149 |
Enrolling by invitation |
Jewish General Hospital |
2021-12-31 |
| NCT02838342 |
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02838342 |
Active, not recruiting |
Centre Hospitalier Universitaire de Besancon |
2020-07-31 |
| NCT02826928 |
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02826928 |
Recruiting |
CHU de Reims |
2022-10-31 |
| NCT02823691 |
The MetNET-2 Trial |
https://ClinicalTrials.gov/show/NCT02823691 |
Recruiting |
National Cancer Institute, Milan |
2022-04-30 |
| NCT02806648 |
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) |
https://ClinicalTrials.gov/show/NCT02806648 |
Completed |
Grupo Espanol de Tumores Neuroendocrinos |
2017-07-31 |
| NCT02754297 |
Personalized PRRT of Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02754297 |
Recruiting |
CHU de Quebec-Universite Laval |
2021-04-30 |
| NCT02749331 |
Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy |
https://ClinicalTrials.gov/show/NCT02749331 |
Recruiting |
Uppsala University |
2022-08-31 |
| NCT02743741 |
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02743741 |
Recruiting |
University Health Network, Toronto |
2024-01-31 |
| NCT02736500 |
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02736500 |
Active, not recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2018-07-31 |
| NCT02736448 |
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02736448 |
Active, not recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2019-08-31 |
| NCT02724540 |
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver |
https://ClinicalTrials.gov/show/NCT02724540 |
Recruiting |
University of Pennsylvania |
2023-03-31 |
| NCT02713763 |
Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib |
https://ClinicalTrials.gov/show/NCT02713763 |
Completed |
Grupo Espanol de Tumores Neuroendocrinos |
2019-10-23 |
| NCT02698410 |
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. |
https://ClinicalTrials.gov/show/NCT02698410 |
Completed |
Ipsen |
2019-02-08 |
| NCT02693067 |
A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver |
https://ClinicalTrials.gov/show/NCT02693067 |
Recruiting |
Provectus Pharmaceuticals |
2020-07-31 |
| NCT02683941 |
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02683941 |
Active, not recruiting |
Ipsen |
2020-02-28 |
| NCT02678780 |
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02678780 |
Completed |
Grupo Espanol de Tumores Neuroendocrinos |
2017-12-31 |
| NCT02651987 |
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg |
https://ClinicalTrials.gov/show/NCT02651987 |
Completed |
Ipsen |
2019-10-16 |
| NCT02611024 |
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors |
https://ClinicalTrials.gov/show/NCT02611024 |
Recruiting |
PharmaMar |
2020-11-30 |
| NCT02609737 |
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02609737 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT02592707 |
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs |
https://ClinicalTrials.gov/show/NCT02592707 |
Active, not recruiting |
Ipsen |
2022-05-31 |
| NCT02589821 |
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02589821 |
Active, not recruiting |
Hutchison Medipharma Limited |
2020-03-30 |
| NCT02589522 |
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02589522 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-30 |
| NCT02588170 |
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02588170 |
Active, not recruiting |
Hutchison Medipharma Limited |
2019-03-31 |
| NCT01229943 |
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01229943 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-09-01 |
| NCT02575300 |
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02575300 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2019-03-26 |
| NCT03197012 |
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT03197012 |
Completed |
University of California, San Francisco |
2019-05-31 |
| NCT03043664 |
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03043664 |
Active, not recruiting |
Duke University |
2020-09-30 |
| NCT02893930 |
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02893930 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-07-31 |
| NCT01253161 |
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) |
https://ClinicalTrials.gov/show/NCT01253161 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2020-12-31 |
| NCT00569127 |
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT00569127 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-01-01 |
| NCT02539433 |
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) |
https://ClinicalTrials.gov/show/NCT02539433 |
Completed |
Northwell Health |
2015-05-31 |
| NCT02489903 |
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) |
https://ClinicalTrials.gov/show/NCT02489903 |
Active, not recruiting |
EpicentRx, Inc. |
2020-12-31 |
| NCT02489604 |
Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02489604 |
Active, not recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2020-12-31 |
| NCT02481804 |
Optimal Feeding for NET Patients |
https://ClinicalTrials.gov/show/NCT02481804 |
Completed |
University Medical Center Groningen |
2016-03-31 |
| NCT02472678 |
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT02472678 |
Completed |
University Medical Center Groningen |
2017-05-31 |
| NCT02464007 |
Study of rSIFN-co for Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02464007 |
Active, not recruiting |
Sichuan Huiyang Life Science and Technology Corporation |
2021-10-31 |
| NCT02441088 |
Theranostics: 68GaDOTATOC and 90YDOTATOC |
https://ClinicalTrials.gov/show/NCT02441088 |
Active, not recruiting |
University of Iowa |
2020-01-31 |
| NCT02441062 |
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02441062 |
Completed |
University of Iowa |
2020-01-20 |
| NCT02420691 |
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin |
https://ClinicalTrials.gov/show/NCT02420691 |
Completed |
M.D. Anderson Cancer Center |
2019-06-05 |
| NCT02402920 |
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT02402920 |
Recruiting |
M.D. Anderson Cancer Center |
2023-07-31 |
| NCT02402062 |
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours |
https://ClinicalTrials.gov/show/NCT02402062 |
Completed |
Grupo Espanol de Tumores Neuroendocrinos |
2018-05-31 |
| NCT02399215 |
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02399215 |
Active, not recruiting |
Roswell Park Cancer Institute |
2020-08-01 |
| NCT02358356 |
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study |
https://ClinicalTrials.gov/show/NCT02358356 |
Recruiting |
Australasian Gastro-Intestinal Trials Group |
2018-12-31 |
| NCT02355535 |
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 |
https://ClinicalTrials.gov/show/NCT02355535 |
Recruiting |
Vanquish Oncology, Inc. |
2019-12-31 |
| NCT02348749 |
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies |
https://ClinicalTrials.gov/show/NCT02348749 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT02315625 |
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery |
https://ClinicalTrials.gov/show/NCT02315625 |
Completed |
National Institutes of Health Clinical Center (CC) |
2019-05-22 |
| NCT02305810 |
A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus |
https://ClinicalTrials.gov/show/NCT02305810 |
Completed |
European Institute of Oncology |
2017-01-12 |
| NCT02299089 |
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) |
https://ClinicalTrials.gov/show/NCT02299089 |
Completed |
Camurus AB |
2016-05-31 |
| NCT02288377 |
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) |
https://ClinicalTrials.gov/show/NCT02288377 |
Completed |
Federation Francophone de Cancerologie Digestive |
2020-01-31 |
| NCT02279602 |
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study |
https://ClinicalTrials.gov/show/NCT02279602 |
Completed |
Mateon Therapeutics |
2016-08-31 |
| NCT02267967 |
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02267967 |
Completed |
Hutchison Medipharma Limited |
2017-08-23 |
| NCT02259725 |
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02259725 |
Active, not recruiting |
University of Southern California |
2020-08-16 |
| NCT02246127 |
Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET) |
https://ClinicalTrials.gov/show/NCT02246127 |
Active, not recruiting |
Grupo Espanol de Tumores Neuroendocrinos |
2019-12-31 |
| NCT04452396 |
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia |
https://ClinicalTrials.gov/show/NCT04452396 |
Recruiting |
Barts & The London NHS Trust |
2020-11-18 |
| NCT02231762 |
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET |
https://ClinicalTrials.gov/show/NCT02231762 |
Completed |
Ipsen |
2016-12-31 |
| NCT02185443 |
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases |
https://ClinicalTrials.gov/show/NCT02185443 |
Recruiting |
University of Sao Paulo |
2021-05-31 |
| NCT02174549 |
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer |
https://ClinicalTrials.gov/show/NCT02174549 |
Active, not recruiting |
Teclison Ltd. |
2020-08-31 |
| NCT02162446 |
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET |
https://ClinicalTrials.gov/show/NCT02162446 |
Completed |
Ipsen |
2015-06-30 |
| NCT02159989 |
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02159989 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02132468 |
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers |
https://ClinicalTrials.gov/show/NCT02132468 |
Completed |
Mateon Therapeutics |
2016-06-30 |
| NCT02125929 |
Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms |
https://ClinicalTrials.gov/show/NCT02125929 |
Completed |
Peking Union Medical College Hospital |
2014-12-31 |
| NCT02125474 |
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate |
https://ClinicalTrials.gov/show/NCT02125474 |
Completed |
Instituto Nacional de Cancerologia, Columbia |
2019-10-31 |
| NCT02113800 |
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study |
https://ClinicalTrials.gov/show/NCT02113800 |
Recruiting |
AIO-Studien-gGmbH |
2019-09-30 |
| NCT02101918 |
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02101918 |
Completed |
National Cancer Institute (NCI) |
2018-01-31 |
| NCT02077933 |
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors |
https://ClinicalTrials.gov/show/NCT02077933 |
Completed |
Novartis |
2019-04-12 |
| NCT02075606 |
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients |
https://ClinicalTrials.gov/show/NCT02075606 |
Completed |
Ipsen |
2017-06-30 |
| NCT02067988 |
Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study |
https://ClinicalTrials.gov/show/NCT02067988 |
Completed |
UMC Utrecht |
2019-09-01 |
| NCT02063958 |
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT02063958 |
Completed |
Esanex Inc. |
2017-03-27 |
| NCT01317615 |
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation |
https://ClinicalTrials.gov/show/NCT01317615 |
Completed |
Novartis |
2015-03-31 |
| NCT01290536 |
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases |
https://ClinicalTrials.gov/show/NCT01290536 |
Completed |
University of California, San Francisco |
2013-10-31 |
| NCT01280201 |
Pazopanib as Single Agent in Advanced NETs |
https://ClinicalTrials.gov/show/NCT01280201 |
Completed |
Grupo Espanol de Tumores Neuroendocrinos |
2013-04-30 |
| NCT01873248 |
Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients |
https://ClinicalTrials.gov/show/NCT01873248 |
Completed |
Jonsson Comprehensive Cancer Center |
2017-06-16 |
| NCT01869725 |
Ga-DOTATOC Versus Octreoscan + CT |
https://ClinicalTrials.gov/show/NCT01869725 |
Completed |
University of Iowa |
2018-12-26 |
| NCT01849523 |
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study |
https://ClinicalTrials.gov/show/NCT01849523 |
Completed |
University Medical Center Groningen |
2014-08-31 |
| NCT01842165 |
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs |
https://ClinicalTrials.gov/show/NCT01842165 |
Recruiting |
Jules Bordet Institute |
2019-06-30 |
| NCT01841736 |
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors |
https://ClinicalTrials.gov/show/NCT01841736 |
Active, not recruiting |
National Cancer Institute (NCI) |
2019-03-05 |
| NCT01824875 |
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01824875 |
Active, not recruiting |
Eastern Cooperative Oncology Group |
2023-06-01 |
| NCT01794793 |
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies |
https://ClinicalTrials.gov/show/NCT01794793 |
Active, not recruiting |
Novartis |
2023-06-09 |
| NCT01784861 |
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01784861 |
Active, not recruiting |
Washington University School of Medicine |
2020-09-30 |
| NCT01747096 |
TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01747096 |
Completed |
Nantes University Hospital |
2016-05-31 |
| NCT01744249 |
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas |
https://ClinicalTrials.gov/show/NCT01744249 |
Active, not recruiting |
Grupo Espanol de Tumores Neuroendocrinos |
2020-11-30 |
| NCT01730417 |
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG |
https://ClinicalTrials.gov/show/NCT01730417 |
Completed |
Duke University |
2011-06-30 |
| NCT01678664 |
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors |
https://ClinicalTrials.gov/show/NCT01678664 |
Completed |
Federation Francophone de Cancerologie Digestive |
2018-09-30 |
| NCT01673906 |
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours |
https://ClinicalTrials.gov/show/NCT01673906 |
Completed |
Arcispedale Santa Maria Nuova-IRCCS |
2015-08-31 |
| NCT01658436 |
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. |
https://ClinicalTrials.gov/show/NCT01658436 |
Completed |
Novartis |
2015-07-31 |
| NCT01638533 |
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT01638533 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-11-29 |
| NCT01619865 |
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors |
https://ClinicalTrials.gov/show/NCT01619865 |
Active, not recruiting |
University of Iowa |
2017-08-27 |
| NCT01595009 |
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) |
https://ClinicalTrials.gov/show/NCT01595009 |
Completed |
Novartis |
2016-08-09 |
| NCT01590199 |
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs |
https://ClinicalTrials.gov/show/NCT01590199 |
Completed |
Novartis |
2018-09-11 |
| NCT01578239 |
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours |
https://ClinicalTrials.gov/show/NCT01578239 |
Active, not recruiting |
Advanced Accelerator Applications |
2015-07-31 |
| NCT01548482 |
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01548482 |
Completed |
National Cancer Institute (NCI) |
2014-01-31 |
| NCT03972488 |
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET |
https://ClinicalTrials.gov/show/NCT03972488 |
Recruiting |
Advanced Accelerator Applications |
2023-12-31 |
| NCT01525550 |
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01525550 |
Completed |
Pfizer |
2016-03-19 |
| NCT01525082 |
Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01525082 |
Active, not recruiting |
Stanford University |
2018-01-31 |
| NCT01524783 |
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) |
https://ClinicalTrials.gov/show/NCT01524783 |
Active, not recruiting |
Novartis |
2014-11-28 |
| NCT01476592 |
A Biological Study of Resveratrol’s Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors |
https://ClinicalTrials.gov/show/NCT01476592 |
Completed |
University of Wisconsin, Madison |
2013-10-31 |
| NCT01469572 |
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases |
https://ClinicalTrials.gov/show/NCT01469572 |
Completed |
Emory University |
2018-10-31 |
| NCT01465659 |
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT01465659 |
Active, not recruiting |
Northwestern University |
2018-07-30 |
| NCT01456078 |
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01456078 |
Completed |
Lund University Hospital |
2018-11-30 |
| NCT01396382 |
68Ga-DOTATATE PET Scan in Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT01396382 |
Completed |
Vanderbilt-Ingram Cancer Center |
2014-05-31 |
| NCT01384617 |
Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy |
https://ClinicalTrials.gov/show/NCT01384617 |
Completed |
Wakayama Medical University |
2014-06-30 |
| NCT01324492 |
Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT01324492 |
Completed |
Novartis |
2014-06-30 |
| NCT04375267 |
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours |
https://ClinicalTrials.gov/show/NCT04375267 |
Recruiting |
Vastra Gotaland Region |
2022-06-30 |
| NCT04362436 |
TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets |
https://ClinicalTrials.gov/show/NCT04362436 |
Recruiting |
Imperial College London |
2022-09-30 |
| NCT04318561 |
Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04318561 |
Recruiting |
Peking Union Medical College Hospital |
2021-12-01 |
| NCT04296149 |
Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe |
https://ClinicalTrials.gov/show/NCT04296149 |
Completed |
European Institute of Oncology |
2018-12-31 |
| NCT04258592 |
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04258592 |
Recruiting |
Universitaire Ziekenhuizen Leuven |
2021-06-01 |
| NCT04207463 |
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04207463 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-12-31 |
| NCT04197310 |
Cabozantinib and Nivolumab for Carcinoid Tumors |
https://ClinicalTrials.gov/show/NCT04197310 |
Recruiting |
Dana-Farber Cancer Institute |
2021-12-26 |
| NCT04194125 |
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT04194125 |
Recruiting |
University of Warmia and Mazury |
2020-06-30 |
| NCT04166006 |
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. |
https://ClinicalTrials.gov/show/NCT04166006 |
Recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2022-06-30 |
| NCT04129255 |
Octreotide LAR in the Induction of Immunologic Response in NENs Patients |
https://ClinicalTrials.gov/show/NCT04129255 |
Active, not recruiting |
National Cancer Institute, Naples |
2019-12-01 |
| NCT04123262 |
Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression |
https://ClinicalTrials.gov/show/NCT04123262 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-06-30 |
| NCT04104529 |
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department |
https://ClinicalTrials.gov/show/NCT04104529 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2024-10-31 |
| NCT04074135 |
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04074135 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2036-01-30 |
| NCT04073017 |
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency |
https://ClinicalTrials.gov/show/NCT04073017 |
Recruiting |
Vanderbilt-Ingram Cancer Center |
2021-04-30 |
| NCT04041882 |
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT04041882 |
Recruiting |
Peking Union Medical College Hospital |
2020-12-30 |
| NCT04040088 |
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04040088 |
Recruiting |
Mayo Clinic |
2023-07-10 |
| NCT04029428 |
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression |
https://ClinicalTrials.gov/show/NCT04029428 |
Recruiting |
University of Warmia and Mazury |
2021-01-01 |
| NCT03986593 |
Cryoablation of Bone Metastases From Endocrine Tumors |
https://ClinicalTrials.gov/show/NCT03986593 |
Recruiting |
Instituto do Cancer do Estado de São Paulo |
2021-06-15 |
| NCT03980925 |
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. |
https://ClinicalTrials.gov/show/NCT03980925 |
Recruiting |
Grupo Espanol de Tumores Neuroendocrinos |
2021-09-30 |
| NCT03950609 |
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors |
https://ClinicalTrials.gov/show/NCT03950609 |
Recruiting |
M.D. Anderson Cancer Center |
2021-05-07 |
| NCT03935893 |
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers |
https://ClinicalTrials.gov/show/NCT03935893 |
Recruiting |
University of Pittsburgh |
2029-06-01 |
| NCT03910660 |
A Trial of BXCL701 and Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer |
https://ClinicalTrials.gov/show/NCT03910660 |
Recruiting |
BioXcel Therapeutics Inc |
2022-04-02 |
| NCT03891784 |
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03891784 |
Recruiting |
University of Washington |
2023-09-30 |
| NCT03883776 |
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03883776 |
Completed |
Universitaire Ziekenhuizen Leuven |
2019-10-29 |
| NCT03881306 |
DEBOXA for Inoperable NET Liver Metastases |
https://ClinicalTrials.gov/show/NCT03881306 |
Recruiting |
Xiangya Hospital of Central South University |
2020-12-31 |
| NCT03879694 |
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03879694 |
Recruiting |
Roswell Park Cancer Institute |
2020-07-17 |
| NCT03873870 |
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03873870 |
Recruiting |
University Health Network, Toronto |
2024-04-01 |
| NCT03834701 |
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms |
https://ClinicalTrials.gov/show/NCT03834701 |
Recruiting |
Catholic University of the Sacred Heart |
2021-06-01 |
| NCT03734913 |
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03734913 |
Recruiting |
Guangdong Zhongsheng Pharmaceutical Co., Ltd. |
2020-11-01 |
| NCT03728361 |
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT03728361 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-12-31 |
| NCT03724409 |
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases |
https://ClinicalTrials.gov/show/NCT03724409 |
Recruiting |
University of Iowa |
2025-12-31 |
| NCT03722511 |
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs |
https://ClinicalTrials.gov/show/NCT03722511 |
Recruiting |
University of Kentucky |
2020-08-31 |
| NCT03673943 |
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE |
https://ClinicalTrials.gov/show/NCT03673943 |
Completed |
Radiomedix, Inc. |
2019-03-23 |
| NCT03670030 |
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System |
https://ClinicalTrials.gov/show/NCT03670030 |
Recruiting |
Ochsner Health System |
2020-05-01 |
| NCT03667092 |
Exploration of Molecular Biomarkers for Lu-177 DOTATATE Therapy in Midgut Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT03667092 |
Recruiting |
University Hospital, Toulouse |
2021-08-31 |
| NCT03629847 |
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue |
https://ClinicalTrials.gov/show/NCT03629847 |
Recruiting |
King Faisal Specialist Hospital & Research Center |
2018-12-31 |
| NCT03600233 |
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03600233 |
Recruiting |
TaiRx, Inc. |
2021-11-30 |
| NCT03591731 |
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) |
https://ClinicalTrials.gov/show/NCT03591731 |
Recruiting |
Intergroupe Francophone de Cancerologie Thoracique |
2021-10-31 |
| NCT03590119 |
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases |
https://ClinicalTrials.gov/show/NCT03590119 |
Recruiting |
UMC Utrecht |
2021-09-01 |
| NCT03582475 |
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate |
https://ClinicalTrials.gov/show/NCT03582475 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2020-09-01 |
| NCT03511768 |
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms |
https://ClinicalTrials.gov/show/NCT03511768 |
Recruiting |
Xiangya Hospital of Central South University |
2019-12-30 |
| NCT03478358 |
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03478358 |
Recruiting |
Peking Union Medical College Hospital |
2019-12-01 |
| NCT03475953 |
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors |
https://ClinicalTrials.gov/show/NCT03475953 |
Recruiting |
Institut Bergonié |
2020-11-30 |
| NCT03466216 |
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET |
https://ClinicalTrials.gov/show/NCT03466216 |
Recruiting |
Radiomedix, Inc. |
2020-07-31 |
| NCT03457948 |
Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases |
https://ClinicalTrials.gov/show/NCT03457948 |
Recruiting |
University of California, San Francisco |
2020-11-30 |
| NCT03454763 |
Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors |
https://ClinicalTrials.gov/show/NCT03454763 |
Recruiting |
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
2021-05-31 |
| NCT03453489 |
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm |
https://ClinicalTrials.gov/show/NCT03453489 |
Recruiting |
Barbara Ann Karmanos Cancer Institute |
2020-06-01 |
| NCT03422029 |
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients |
https://ClinicalTrials.gov/show/NCT03422029 |
Recruiting |
Peking University |
2020-12-30 |
| NCT03420521 |
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT03420521 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2023-01-15 |
| NCT03411915 |
A Study of XmAb®18087 in Subjects With NET and GIST |
https://ClinicalTrials.gov/show/NCT03411915 |
Recruiting |
Xencor, Inc. |
2021-03-31 |
| NCT01263353 |
Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs |
https://ClinicalTrials.gov/show/NCT01263353 |
Completed |
Novartis |
2014-03-31 |
| NCT01262235 |
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients |
https://ClinicalTrials.gov/show/NCT01262235 |
Completed |
Arbutus Biopharma Corporation |
2015-07-31 |
| NCT01218555 |
Study of Everolimus (RAD001) in Combination With Lenalidomide |
https://ClinicalTrials.gov/show/NCT01218555 |
Completed |
Emory University |
2017-05-31 |
| NCT01204476 |
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT01204476 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01177397 |
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01177397 |
Completed |
Celgene |
2016-11-15 |
| NCT01169649 |
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) |
https://ClinicalTrials.gov/show/NCT01169649 |
Completed |
Memorial Sloan Kettering Cancer Center |
2014-02-28 |
| NCT01121562 |
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01121562 |
Completed |
Pfizer |
2011-07-31 |
| NCT01099540 |
Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT01099540 |
Completed |
Samsung Medical Center |
2012-03-31 |
| NCT01099228 |
Combination Targeted Radiotherapy in Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01099228 |
Completed |
University of Iowa |
2008-04-30 |
| NCT01024387 |
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01024387 |
Completed |
Dana-Farber Cancer Institute |
2016-01-31 |
| NCT01010126 |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
https://ClinicalTrials.gov/show/NCT01010126 |
Completed |
National Cancer Institute (NCI) |
2017-03-13 |
| NCT00990535 |
High Dose Somatostatin Analogues in Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00990535 |
Completed |
Federico II University |
2007-12-31 |
| NCT00978211 |
DOTA-TOC in Metastasized Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00978211 |
Completed |
University Hospital, Basel, Switzerland |
2013-09-30 |
| NCT00965250 |
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy |
https://ClinicalTrials.gov/show/NCT00965250 |
Completed |
National Institutes of Health Clinical Center (CC) |
2012-03-31 |
| NCT00953394 |
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00953394 |
Completed |
University of Turin, Italy |
2006-02-28 |
| NCT00942682 |
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00942682 |
Completed |
Dana-Farber Cancer Institute |
2013-03-31 |
| NCT03870399 |
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression |
https://ClinicalTrials.gov/show/NCT03870399 |
Recruiting |
AC Camargo Cancer Center |
2022-03-13 |
| NCT00869050 |
Capecitabine and Temozolomide for Neuroendocrine Cancers |
https://ClinicalTrials.gov/show/NCT00869050 |
Completed |
Columbia University |
2013-12-31 |
| NCT00843531 |
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00843531 |
Completed |
University of California, San Francisco |
2013-07-31 |
| NCT04440956 |
An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours |
https://ClinicalTrials.gov/show/NCT04440956 |
Completed |
Clarity Pharmaceuticals Ltd |
2016-02-25 |
| NCT04385992 |
Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET |
https://ClinicalTrials.gov/show/NCT04385992 |
Recruiting |
IRCCS San Raffaele |
2021-11-30 |
| NCT01970540 |
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors |
https://ClinicalTrials.gov/show/NCT01970540 |
Completed |
PharmaMar |
2017-08-09 |
| NCT01364415 |
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) |
https://ClinicalTrials.gov/show/NCT01364415 |
Completed |
Novartis |
2016-04-30 |
| NCT03981614 |
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT03981614 |
Recruiting |
Academic and Community Cancer Research United |
2020-12-28 |
| NCT00804336 |
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00804336 |
Completed |
Dana-Farber Cancer Institute |
2014-09-30 |
| NCT02568267 |
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) |
https://ClinicalTrials.gov/show/NCT02568267 |
Recruiting |
Hoffmann-La Roche |
2022-12-01 |
| NCT01466036 |
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors |
https://ClinicalTrials.gov/show/NCT01466036 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-09-30 |
| NCT04079712 |
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT04079712 |
Recruiting |
National Cancer Institute (NCI) |
2021-10-01 |
| NCT01967537 |
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT01967537 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-12-17 |
| NCT01845675 |
Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor |
https://ClinicalTrials.gov/show/NCT01845675 |
Completed |
Peking Union Medical College Hospital |
2016-11-30 |
| NCT04077372 |
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers |
https://ClinicalTrials.gov/show/NCT04077372 |
Recruiting |
Stanford University |
2020-09-30 |
| NCT00781911 |
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer |
https://ClinicalTrials.gov/show/NCT00781911 |
Completed |
Eli Lilly and Company |
2011-07-31 |
| NCT00780663 |
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma |
https://ClinicalTrials.gov/show/NCT00780663 |
Completed |
Cylene Pharmaceuticals |
2010-03-31 |
| NCT00688623 |
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe |
https://ClinicalTrials.gov/show/NCT00688623 |
Completed |
Novartis |
2016-11-07 |
| NCT00681187 |
Somatuline Autogel Preference and Health Economy Study |
https://ClinicalTrials.gov/show/NCT00681187 |
Completed |
Ipsen |
2010-08-31 |
| NCT00610129 |
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) |
https://ClinicalTrials.gov/show/NCT00610129 |
Completed |
Memorial Sloan Kettering Cancer Center |
2010-01-31 |
| NCT00605566 |
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00605566 |
Completed |
University Health Network, Toronto |
2015-02-28 |
| NCT00602082 |
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00602082 |
Completed |
National Cancer Institute (NCI) |
2009-12-31 |
| NCT00590343 |
Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00590343 |
Completed |
Louisiana State University Health Sciences Center in New Orleans |
2010-03-31 |
| NCT00576680 |
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00576680 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2019-08-31 |
| NCT00510068 |
Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00510068 |
Completed |
Novartis |
2010-02-28 |
| NCT00454363 |
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer |
https://ClinicalTrials.gov/show/NCT00454363 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT00442533 |
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00442533 |
Completed |
Radio Isotope Therapy of America |
2014-08-30 |
| NCT00434109 |
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization |
https://ClinicalTrials.gov/show/NCT00434109 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2012-02-29 |
| NCT00428220 |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. |
https://ClinicalTrials.gov/show/NCT00428220 |
Completed |
Pfizer |
2014-08-31 |
| NCT00427349 |
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00427349 |
Completed |
Eastern Cooperative Oncology Group |
2014-10-31 |
| NCT00424723 |
Pemetrexed in Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00424723 |
Completed |
Dana-Farber Cancer Institute |
2007-01-31 |
| NCT00398320 |
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00398320 |
Completed |
Stanford University |
2012-10-31 |
| NCT00363051 |
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy |
https://ClinicalTrials.gov/show/NCT00363051 |
Completed |
Novartis |
2008-01-31 |
| NCT00326469 |
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours |
https://ClinicalTrials.gov/show/NCT00326469 |
Completed |
Ipsen |
2009-11-30 |
| NCT00230139 |
SPECT/CT in Endocrine and Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00230139 |
Completed |
Rambam Health Care Campus |
2004-01-31 |
| NCT00171873 |
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut |
https://ClinicalTrials.gov/show/NCT00171873 |
Completed |
Philipps University Marburg Medical Center |
2008-06-30 |
| NCT00165230 |
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00165230 |
Completed |
Dana-Farber Cancer Institute |
2006-07-31 |
| NCT00137774 |
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00137774 |
Completed |
Dana-Farber Cancer Institute |
2005-07-31 |
| NCT00131911 |
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00131911 |
Completed |
National Cancer Institute (NCI) |
2010-10-31 |
| NCT00017199 |
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00017199 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00075439 |
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00075439 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00004922 |
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00004922 |
Completed |
Memorial Sloan Kettering Cancer Center |
2002-06-30 |
| NCT00056693 |
Treatment With SU11248 in Patients With Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00056693 |
Completed |
Pfizer |
2006-09-30 |
| NCT00027638 |
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00027638 |
Completed |
Memorial Sloan Kettering Cancer Center |
2003-12-31 |
| NCT00050349 |
EPO906 in Carcinoid and Other Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00050349 |
Completed |
Novartis |
2007-04-30 |
| NCT00037869 |
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00037869 |
Completed |
M.D. Anderson Cancer Center |
2005-01-31 |
| NCT00501540 |
Lithium for Low-Grade Neuroendocrine Tumors |
https://ClinicalTrials.gov/show/NCT00501540 |
Completed |
University of Wisconsin, Madison |
2009-06-30 |